165 related articles for article (PubMed ID: 37076494)
21. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
22. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
23. Inhomogeneous activity distribution of 177Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice.
Oddstig J; Bernhardt P; Lizana H; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Tumour Biol; 2012 Feb; 33(1):229-39. PubMed ID: 22108870
[TBL] [Abstract][Full Text] [Related]
24. GOT1 xenografted to nude mice: a unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors.
Nilsson O; Kölby L; Bernhardt P; Forssell-Aronsson E; Johanson V; Ahlman H
Ann N Y Acad Sci; 2004 Apr; 1014():275-9. PubMed ID: 15153445
[TBL] [Abstract][Full Text] [Related]
25. Kidney Protection with the Radical Scavenger α
Kristiansson A; Örbom A; Vilhelmsson Timmermand O; Ahlstedt J; Strand SE; Åkerström B
Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439519
[TBL] [Abstract][Full Text] [Related]
26. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
Hubble D; Kong G; Michael M; Johnson V; Ramdave S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1869-75. PubMed ID: 20445977
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
28. Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice.
Bernhardt P; Oddstig J; Kölby L; Nilsson O; Ahlman H; Forssell-Aronsson E
Cancer Biother Radiopharm; 2007 Oct; 22(5):644-53. PubMed ID: 17979567
[TBL] [Abstract][Full Text] [Related]
29. The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice.
Schüler E; Österlund A; Forssell-Aronsson E
Acta Oncol; 2016; 55(1):68-76. PubMed ID: 25813472
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional response of kidney tissue after 177Lu-octreotate administration in mice.
Schüler E; Rudqvist N; Parris TZ; Langen B; Helou K; Forssell-Aronsson E
Nucl Med Biol; 2014 Mar; 41(3):238-47. PubMed ID: 24434014
[TBL] [Abstract][Full Text] [Related]
31. Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour.
Kölby L; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Forssell-Aronsson E; Mäcke H; Nilsson O
Br J Cancer; 2005 Nov; 93(10):1144-51. PubMed ID: 16251870
[TBL] [Abstract][Full Text] [Related]
32. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
Teunissen JJ; Kwekkeboom DJ; Krenning EP
J Clin Oncol; 2004 Jul; 22(13):2724-9. PubMed ID: 15226340
[TBL] [Abstract][Full Text] [Related]
33. Long-term survival and toxicity in patients with neuroendocrine tumors treated with
Kennedy KR; Turner JH; MacDonald WBG; Claringbold PG; Boardman G; Ransom DT
Cancer; 2022 Jun; 128(11):2182-2192. PubMed ID: 35363879
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.
Melis M; Forrer F; Capello A; Bijster M; Bernard BF; Reubi JC; Krenning EP; De Jong M
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):324-33. PubMed ID: 17923824
[TBL] [Abstract][Full Text] [Related]
35. Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions.
van Vliet EI; Hermans JJ; de Ridder MA; Teunissen JJ; Kam BL; de Krijger RR; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2012 Sep; 53(9):1359-66. PubMed ID: 22782312
[TBL] [Abstract][Full Text] [Related]
36. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.
van Vliet EI; Krenning EP; Teunissen JJ; Bergsma H; Kam BL; Kwekkeboom DJ
J Nucl Med; 2013 Oct; 54(10):1689-96. PubMed ID: 24084705
[TBL] [Abstract][Full Text] [Related]
37. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
38. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
van Essen M; Krenning EP; Kam BL; de Herder WW; van Aken MO; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):743-8. PubMed ID: 18188559
[TBL] [Abstract][Full Text] [Related]
39. Safety of multiple repeated cycles of
Yordanova A; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1207-1214. PubMed ID: 28246882
[TBL] [Abstract][Full Text] [Related]
40. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
Khan S; Krenning EP; van Essen M; Kam BL; Teunissen JJ; Kwekkeboom DJ
J Nucl Med; 2011 Sep; 52(9):1361-8. PubMed ID: 21795361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
